HM Payson & Co’s BridgeBio Pharma BBIO Stock Holding History

HM Payson & Co’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-131	Closed	-$2K	–	1055
2021 Q4	$2K	Buy	+131	New	+$5.54K	﹤0.01%	1004
2021 Q2	–	Sell	-284	Closed	-$17K	–	1093
2021 Q1	$17K	Buy	+284	New	+$18.6K	﹤0.01%	791

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HM Payson & Co's BBIO Position: Q1 2022 in Review

HM Payson & Co sold out of BridgeBio Pharma (BBIO) in Q1 2022, closing a stake of 131 shares — an estimated $2K sold.

HM Payson & Co first reported a position in BBIO in Q1 2021 and held it in 2 quarters. The position peaked at $17K in Q1 2021. 178 funds tracked by Wall St. Rank hold BBIO as of Q1 2022.

HM Payson & Co reported no remaining BridgeBio Pharma position as of Q1 2022 after selling out during the quarter.
HM Payson & Co sold 131 BridgeBio Pharma shares in Q1 2022, an estimated $2K.
HM Payson & Co first reported a position in BridgeBio Pharma in Q1 2021 and held it in 2 quarters.
HM Payson & Co's BridgeBio Pharma position peaked at $17K in Q1 2021.
178 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2022.

Based on HM Payson & Co's 13F filing for Q1 2022, filed 12 May 2022.